Difference between revisions of "WHIM syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
|||
(8 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | + | <span id="BackToTop"></span> | |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
− | + | {{#lst:Editorial board transclusions|heme}} | |
− | |||
− | |||
− | |||
− | | | ||
− | |||
'''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis | '''WHIM:''' '''<u>W</u>'''arts, '''<u>H</u>'''ypogammaglobulinemia, '''<u>I</u>'''nfections, '''<u>M</u>'''yelokathexis | ||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 17: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
=All lines of therapy= | =All lines of therapy= | ||
− | |||
==Plerixafor monotherapy {{#subobject:dc6eae|Regimen=1}}== | ==Plerixafor monotherapy {{#subobject:dc6eae|Regimen=1}}== | ||
− | + | <div class="toccolours" style="background-color:#eeeeee"> | |
− | |||
− | |||
− | |||
===Regimen {{#subobject:be34d7|Variant=1}}=== | ===Regimen {{#subobject:be34d7|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Line 30: | Line 19: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https://www. | + | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ McDermott et al. 2019] |
− | |style="background-color:#ffffbe"|Pilot, | + | |style="background-color:#ffffbe"|Pilot, fewer than 20 pts |
|- | |- | ||
|} | |} | ||
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Growth factor therapy==== | ====Growth factor therapy==== | ||
− | *[[Plerixafor (Mozobil)]] | + | *[[Plerixafor (Mozobil)]] 0.01 to 0.02 mg/kg SC twice per day |
− | + | '''Various durations''' | |
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https:// | + | # '''Case series:''' McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. [https://doi.org/10.1056/NEJMoa1808575 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6425947/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/30625055/ PubMed] |
− | |||
[[Category:WHIM syndrome regimens]] | [[Category:WHIM syndrome regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Cytopenias]] | [[Category:Cytopenias]] |
Latest revision as of 13:28, 5 November 2023
Section editor | |
---|---|
Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA |
WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
1 regimens on this page
1 variants on this page
|
All lines of therapy
Plerixafor monotherapy
Regimen
Study | Evidence |
---|---|
McDermott et al. 2019 | Pilot, fewer than 20 pts |
References
- Case series: McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article link to PMC article contains dosing details in manuscript PubMed